GlassScriptPhysician profile
Jason Corwin Wills
NPI 1871689554
$5,725.30
in general payments reported to CMS, 2019-2025
31 companies · $1,091 in 2025
The $1,091 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $660 · 2020: $237 · 2021: $309 · 2022: $934 · 2023: $1,122 · 2024: $1,372 · 2025: $1,091.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,584.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,584.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,255.60 | 2019-2025 | Skyrizi, Rinvoq, Mavyret |
| Takeda Pharmaceuticals U.S.A., INC. | $1,055.85 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Janssen Biotech, INC. | $883.24 | 2019-2025 | Tremfya, Stelara, Simponi |
| Boston Scientific Corporation | $356.86 | 2019-2023 | Alliance II, Exalt Model D, Spyglass |
| Regeneron Healthcare Solutions, INC. | $268.73 | 2022-2025 | Dupixent |
| Genzyme Corporation | $257.37 | 2023-2025 | |
| Pfizer INC. | $195.15 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $190.10 | 2019-2023 | Dificid |
| Aimmune Therapeutics, INC. | $169.63 | 2024-2025 | Zenpep, Vowst |
| Organon LLC | $154.43 | 2021-2025 | Renflexis, Hadlima |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $153.72 | 2019-2025 | Xifaxan, Trulance, Relistor |
| Celgene Corporation | $133.91 | 2022-2024 | Zeposia |
| Qol Medical, LLC | $110.20 | 2022-2023 | Sucraid |
| Celltrion USA INC. | $91.55 | 2024-2025 | Vegzelma, Zymfentra |
| Intercept Pharmaceuticals, INC. | $72.03 | 2021-2024 | Ocaliva |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $50.60 | 2019-2024 | |
| Ardelyx, INC. | $47.34 | 2023-2025 | Ibsrela |
| Madrigal Pharmaceuticals | $40.08 | 2024 | Resmetirom |
| Orphalan INC | $33.38 | 2025 | Cuvrior |
| Allergan, INC. | $33.05 | 2019 | |
| Ucb, INC. | $24.83 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $22.49 | 2024 | Iqirvo |
| Phathom Pharmaceuticals, INC. | $19.07 | 2025 | Voquezna |
| Shire North American Group INC | $18.00 | 2019 | |
| Endo Pharmaceuticals INC. | $17.56 | 2019 | |
| Alexion Pharmaceuticals, INC. | $17.49 | 2019 | |
| Ferring Pharmaceuticals INC. | $14.79 | 2023 | Rebyota |
| Shionogi INC | $13.67 | 2019 | |
| Redhill Biopharma INC. | $13.27 | 2021 | |
| Braintree Laboratories, INC. | $11.31 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$14,973.95 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Wills listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.